The present disclosure relates to methods and agents for enhancing the effect of T cells engineered to express chimeric antigen receptors (CARs). These methods and agents are, in particular, useful for the treatment of diseases characterized by diseased cells expressing an antigen the CAR is directed to. Specifically, the present disclosure relates to methods comprising providing to a subject T cells genetically modified to express a chimeric antigen receptor (CAR) and administering to the subject IL2 or a polynucleotide encoding IL2. The methods of the disclosure may comprise administering IL2 or a polynucleotide encoding IL2 and a further cytokine or a polynucleotide encoding a further cytokine, wherein the further cytokine may be IL7 or IL21. The T cells genetically modified to express a CAR may be provided to the subject by administering the T cells genetically modified to express a CAR or by generating the T cells genetically modified to express a CAR in the subject. The methods of the disclosure may further comprise administering to the subject an antigen or a variant thereof, or a polynucleotide encoding an antigen or a variant thereof, wherein the T cells genetically modified to express a CAR are targeted to the antigen. In one particularly preferred embodiment, the polynucleotides administered according to the present disclosure are RNA.La présente invention concerne des procédés et des agents destinés à améliorer l'effet des lymphocytes T modifiés pour exprimer des récepteurs d'antigènes chimériques (CAR). Ces procédés et agents sont notamment utiles pour le traitement de maladies caractérisées par des cellules malades exprimant un antigène vers lequel est dirigé le CAR. Plus précisément, la présente invention concerne des procédés comprenant la fourniture à un sujet des lymphocytes T génétiquement modifiés pour exprimer un récepteur d'antigène chimère (CAR) et l'administration au sujet d'IL2 ou d'un polynucléotide codant l'IL2. Les procédés de l'invention
